12/1/2003

Celltech will regain its rights to CDP 870, a rheumatoid arthritis and Crohn's Disease drug, after Pfizer wanted to rework the financial terms of its deal with Celltech. The British biotech firm can either find a new partner for the drug or sell it alone.

Related Summaries